MARKET

CNST

CNST

Constellation Pharmaceuticals
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.04
-1.20
-5.16%
Closed 16:29 09/18 EDT
OPEN
23.52
PREV CLOSE
23.24
HIGH
23.52
LOW
21.75
VOLUME
2.54M
TURNOVER
--
52 WEEK HIGH
59.49
52 WEEK LOW
6.01
MARKET CAP
1.05B
P/E (TTM)
-9.1933
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Hedge Funds Are Betting On Constellation Pharmaceuticals, Inc. (CNST)
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend
Insider Monkey · 09/10 14:06
Constellation Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in upcoming virtual investor
GlobeNewswire · 09/09 20:00
Constellation Pharmaceuticals stock price target cut to $20 from $47 at Oppenheimer
CNST | Complete Constellation Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
marketwatch.com · 09/08 12:46
Benzinga's Top Upgrades, Downgrades For September 3, 2020
Upgrades * For AGCO Corp (NYSE: AGCO), B of A Securities upgraded the previous rating of Neutral to the current rating Buy. AGCO earned $1.11 in the second quarter, compared to $1.82 in the year-ago quarter. The current stock performance of AGCO shows a 52-week-high of $81.39 and a 52-week-low of $35.33
Benzinga · 09/03 14:21
Constellation Pharmaceuticals, Inc. (CNST) CEO Jigar Raythatha on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 08/09 17:14
Constellation Pharmaceuticals EPS misses by $0.07
Constellation Pharmaceuticals (NASDAQ:CNST): Q2 GAAP EPS of -$0.70 misses by $0.07. Cash, cash equivalents and marketable securities of $520.5M Press Relea
seekingalpha · 08/05 16:21
Constellation Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 EPS results.
Benzinga · 08/05 12:19
Constellation Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 EPS results.
Benzinga · 08/05 12:19
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CNST stock price target is 45.80 with a high estimate of 75.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 166
Institutional Holdings: 52.55M
% Owned: 110.63%
Shares Outstanding: 47.50M
TypeInstitutionsShares
Increased
57
9.73M
New
57
2.79M
Decreased
18
3.34M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.06%
Pharmaceuticals & Medical Research
+0.57%
Key Executives
Chairman/Independent Director
Mark Goldsmith
President/Chief Executive Officer/Director
Jigar Raythatha
Chief Financial Officer/Senior Vice President/Treasurer
Emma Reeve
Chief Scientific Officer
Patrick Trojer
General Counsel
Karen Valentine
Other
Jeffrey Humphrey
Director
James Audia
Other
Jessica Christo
Independent Director
Scott Braunstein
Independent Director
Steven Hoerter
Independent Director
Richard Levy
Independent Director
Robert Tepper
Independent Director
Elizabeth Trehu
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More

Analyst Price Target

The average CNST stock price target is 45.80 with a high estimate of 75.00 and a low estimate of 20.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CNST
Constellation Pharmaceuticals, Inc. discovers and develops small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders and other diseases. The Company has three clinical-stage oncology development programs: the first program is evaluating a compound, CPI-0610, other program is evaluating a compound, CPI-1205 and CPI-0209 is initiate Phase I clinical trial and targeting solid tumors. CPI-1205 is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. CPI-0610 is a potent and selective small molecule designed to promote anti-tumor activity by selectively inhibiting the function of BET proteins, which are proteins that normally enhance target gene expression. The Company is conducting the ProSTAR trial, which is an open-label Phase Ib/2 clinical trial of CPI-1205 for the treatment of mCRPC in combination with enzalutamide and abiraterone acetate.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Constellation Pharmaceuticals Inc stock information, including NASDAQ:CNST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNST stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CNST stock methods without spending real money on the virtual paper trading platform.